osimertinib
Tagrisso Approved for Some With Locally Advanced, Unresectable Stage III NSCLC Following Chemoradiation
The FDA has approved Tagrisso for adult patients with locally advanced, unresectable stage III NSCLC whose disease ...
SEPTEMBER 26, 2024
For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines
In patients with unresectable EGFRm, stage III NSCLC, Tagrisso appears destined to become the new standard ...
JULY 18, 2024
Load more